Opinion|Videos|January 22, 2025
Adverse Event Management and Patient Safety With Revumenib
Panelists discuss the most commonly seen adverse effects (AEs) in menin inhibitor treatment, strategies for managing and mitigating these AEs to optimize outcomes, and how they compare across approved and pipeline menin inhibitors, along with best practices for clinicians to manage differentiation syndrome, a critical safety concern.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What AEs are most commonly seen and how do you mitigate or manage these to optimize outcomes and maintain treatment continuity?
- Do these AEs align with what you’d expect when treating these patients?
- How do they compare across both approved and pipeline menin inhibitors?
- Differentiation syndrome, while manageable, is a critical safety concern,. hHow can clinicians best prepare to manage this?
Advertisement
Related to this article
A pilot study represents a milestone toward testing a faster, more powerful, and potentially less-toxic form of radiation therapy for cancer treatment.
Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
UTRxMYCN M1-14 received orphan drug status for soft tissue sarcoma and RPDD for rhabdomyosarcoma.
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Plinabulin Plus Docetaxel in Post-ICI Non-Squamous NSCLC
2
Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026
3
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
4
Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape
5